Results 31 to 40 of about 2,741,553 (288)

Mechanism of thyroid-hormone regulated expression of the SERCA genes in skeletal muscle: Implications for thermogenesis [PDF]

, 2001
Thyroid hormone increases the Ca2+-ATPase activity of the sarcoplasmic reticulum (SR) in skeletal muscle, thereby increasing the energy-turnover associated with Ca2+-cycling during contraction and rest. The fast-muscle isoform of the Ca2+-ATPase (SERCA1)
Hardeveld, C., Muller, A., Van der Linden, C. G., Simonides, W.S., Van Hardeveld, C., van der Linden, C.G., Thelen, M.H.M., Linden, C.G., van der, Simonides, W. S., Thelen, M. H.M.   +9 more
core   +1 more source

Macro-Thyroid-Stimulating Hormone Is a Rare Cause of Elevated Thyroid-Stimulating Hormone Levels: Two Cases and Review of the Literature

Endocrinology Research and Practice, 2023
In patients with elevated thyroid-stimulating hormone levels but clinically euthyroid, non-thyroid causes of thyroid-stimulating hormone elevation should be considered.
Fatma Tuğçe Şah Ünal, Sevim Güllü
doaj  

Thyroid Hormone Resistance Syndromes

, 2019
Syndromes with impaired sensitivity to thyroid hormone (TH) include three types of resistance to thyroid hormone (RTH) syndromes (RTHβ, RTHα, and nonTR-RTH) and also include patients with defects in TH transport into cells (thyroid hormone cell membrane ...
Refetoff, Samuel, Roy E. Weiss, Samuel Refetoff, Weiss, Roy E   +3 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

Thyroid hormone resistance in two patients with papillary thyroid microcarcinoma and their BRAFV600E mutation status

Archives of Endocrinology and Metabolism
Resistance to thyroid hormone (RTH) is a rare autosomal dominant hereditary disorder. Here in, we report two patients with RTH in whom differentiated thyroid cancer was diagnosed. Two patients were admitted to our clinic and their laboratory results were
Melia Karakose, Mustafa Caliskan, Muyesser Sayki Arslan, Erman Cakal, Ahmet Yesilyurt, Tuncay Delibasi   +5 more
doaj   +1 more source

Thyroid Hormone Resistance in a Preterm Infant with a Novel THRB Mutation [PDF]

Neonatal Medicine, 2019
Resistance to thyroid hormone (RTH) is a condition caused by a mutation in the thyroid hormone receptor gene. It is rarely reported in individuals with no family history of RTH or in premature infants, and its clinical presentation varies. In our case, a
Joon Yeol Bae, Dong Yeop Kim, Young Dai Kwon, Young Hwa Song, Han Hyuk Lim, Hyung-Doo Park, Jae Woo Lim   +6 more
doaj   +1 more source

Alopecia: Association with Resistance to Thyroid Hormones

Journal of Pediatric Endocrinology and Metabolism, 2009
Resistance to thyroid hormone (RTH) syndrome is caused by thyroid hormone beta receptor (TRbeta) mutations. Goiter, learning disabilities, psychological abnormalities, sinus tachycardia, hearing deficits, short stature, and growth delay are among the most common symptoms in patients with RTH.
Güran, Tülay, Bircan, Rifat, Turan, Serap, Bereket, Abdullah   +3 more
openaire   +5 more sources